A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Phase 1 Completed 58 enrolled Genentech, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid tumors and patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen.

Timeline

Start: 2009-09
Primary completion: 2014-09
Completion: 2014-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pictilisib	Small molecule	—	Oral
Background	Erlotinib	Small molecule	—	Oral

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications